Alvimopan is a peripherally acting μ opioid antagonist. It is acclimated to abstain postoperative ileus afterward baby or ample bowel resection and accelerates the gastrointestinal accretion period.
Alvimopan competitively binds to mu-opioid receptor in the gastrointestinal tract. Unlike methylnaltrexone (another peripherally acting mu-receptor antagonist) that bears a quaternary amine, alvimopan owes its selectivity for borderline receptors to its kinetics. Alvimopan binds to borderline mu-receptors with a Ki of 0.2 ng/mL and dissociates slower than a lot of added ligands.
Used to advance the time to high and lower gastrointestinal accretion afterward fractional ample or baby bowel resection anaplasty with primary anastomosis. Also advised for use in the analysis of affliction (acute or chronic).